Neoadjuvant Dupilumab in Men With Localized High-Risk Prostate Cancer

NCT03886493 · clinicaltrials.gov ↗

PHASE2

Phase

TERMINATED

Status

7

Enrollment

OTHER

Sponsor class

Stopped Low accrual due to COVID-19 pandemic.

Conditions

Prostate Cancer

Interventions

DRUG: Dupilumab

Sponsor

Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins

Collaborators

[object Object]